Please assess the completion status of the following clinical trial:

Trial Title: Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Adult patients with confident diagnosis of mild to moderate IPF, who had previously not yet been treated with Pirfenidone~Exclusion Criteria:~Hypersensitivity to the active substance or one of the other excipients of Pirfenidone Concomitant use of Fluvoxamin Severe hepatic impairment or end stage liver disease Severe renal impairment (Creatinine-Clearance \<30 ml/min) or end stage renal disease requiring dialysis Simultaneous participation in interventional studies Previously treated with Pirfenidone for longer than 30 days

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with idiopathic pulmonary fibrosis (Type: None): Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.

Based on this trial design, predict the completion outcome and termination type (if applicable).